📊 Backtest📒 Journal Updated 13/08/2026
← ⚡ Catalyst
📐 Simulate Position
STALE?Report written 7 days ago · at $4.19entry levels may be stale — re-check before acting

CAPR

ค่าขนมSMALL CAP
Capricor Therapeutics, Inc. · NASDAQ · Healthcare / Biotechnology (Cell Therapy)
$4.19
▲ 6.62%
MCap $0.24B
BusinessCell therapy · Deramiocel for Duchenne muscular dystrophy cardiomyopathy — thesis materially broken by a 9-3 negative FDA advisory committee vote
Thesis

⚠️ THESIS BROKEN — this report replaces the Jul 14 version, which modelled a Base case of +70% to $35.04 on the assumption the FDA advisory committee would go Capricor's way. It did not. An FDA briefing document on Jul 27 challenged the statistical validity of the Phase 3 HOPE-3 results, and the AdCom then voted 9-3 that the evidence does NOT establish deramiocel's effectiveness in DMD cardiomyopathy. The stock fell from $22.43 (Jul 6) to $4.19 — down 81% — analysts cut targets from the $38-63 range into single digits, and securities fraud class actions have been filed. The Aug 22 PDUFA still stands and the AdCom vote is formally non-binding, so a surprise approval is not impossible, but the base case is now a CRL. At $4.19 this is ค่าขนม — a lottery ticket on an FDA reversal, not a position.

📝 Primary Verdict · Core Holding
SPECULATIVEค่าขนม

Thesis broken — not a new position. Existing holders: this is now a binary lottery on an FDA reversal, size accordingly. Do NOT average down toward the old $17-18.50 entry from the prior report.

65
score / 100 ⓘ
⚡ Catalyst
⚖️ FDA PDUFA Decision (2nd review cycle)9 DAYS

Target action date stands at Aug 22 despite the negative advisory committee vote. The FDA is not bound by the AdCom recommendation and weighs it alongside the full administrative record — but approving over a 9-3 negative vote on an efficacy question would be unusual.

Aug 22, 2026
⚠️ Securities Class Action ExposureONGOING

Multiple securities fraud suits filed alleging the company misrepresented the integrity of its trial data and statistical analysis plan. This is a claim on cash for a company that now has limited access to equity markets.

Ongoing
🎯 Entry Point
Entry 1
$4.19
Current price — only as ค่าขนม sizing on an FDA reversalLottery ticket only
Entry 2PREFERRED
$2.8–3.2
Post-CRL washout — where a pipeline/cash-value case could be re-examinedAfter the event
Entry 3
$1.80
Distress — assumes dilution and litigation reserveDeep dip
✅ Take Profit
TP1
Relief bounce if the FDA signals flexibility before Aug 22
$6
+43.2%
TP2
Surprise approval over the AdCom vote
$9
+114.8%
TP3 🌙
Approval plus a workable label · 2027
$13
+210.3%
🔴 Stop Loss
Tight Stop
Wider than the measured core medianMAE of -14% as the stop rule requires — though on a name this damaged the honest guidance is position size, not stop placement
$3.3
-21.2%
Hard Stop
Below this the market is pricing dilution plus litigation
$2.5
-40.3%
Risk / Reward
Tight stop (-21.2%) vs TP2 (+114.8%)
5.4 : 1
⚠ ⚠️ R/R is misleading here — a CRL gaps through any stop overnight, and the 9-3 vote means the unfavourable branch is the base case, not the tail
📅 Estimate Date
PDUFA Decision
Approve vs CRL — base case is CRL after the 9-3 vote
Aug 22, 2026
CRL more likely than not
Q3 2026 Earnings
Cash runway and litigation reserve are the only numbers that matter
Nov 2026
n/a — pre-revenue
📈 Stock Timeline
2 snapshots · Jul 14 → Aug 13
Score
▼ 43
28
Jul 14Aug 13
TP2 Target
▼ 46
$9
Jul 14Aug 13
Rank
▲ 1
#16
Jul 14Aug 13
📈 Possible Up % — Scenario Spread
Bear
-57%
$1.8
Base
-14.1%
$3.6
Bull
+114.8%
$9
Moon
+210.3%
$13
← downsideupside →
🏛️ Fed / Macro Risk — LOW

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Fed funds held at 3.50-3.75% on Jul 29 (fifth consecutive pause, three dissents for a hike). Next FOMC Sep 16, after the Aug 22 PDUFA.
Inflation
July CPI (Aug 12) headline 3.4%, core 2.5%, +0.1% m/m — soft, easing hike pressure.
Sector Impact
Irrelevant to this name right now. A binary regulatory outcome and litigation risk dominate anything rates do to a $0.24B pre-revenue biotech.
Summary
LOW — macro is not what is wrong here.
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

CAPR❌ BadJul 2026
-81%
in 30 days
FDA briefing document challenges HOPE-3 statistics, AdCom votes 9-3 against effectiveness
The event that broke this thesis. From $22.43 (Jul 6) to $4.17 (Aug 4). This is the case, not an analogue.
CAPR❌ BadJul 2025
-30%
in 1 day
Complete Response Letter, first review cycle
Same drug, same company, prior cycle. The -30% is the floor reference for a CRL that the market partly expects — this time far more is already priced in.
SRPT✅ GoodJun 2023
+30%
in 2 days
Accelerated approval in DMD despite advisory committee controversy
The precedent for FDA approving in DMD over advisory objections — the reason the bull branch is not zero. But SRPT's vote was narrow, not 9-3, so this overstates CAPR's odds.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-21.2% / -40%) only when trading the earnings spot — not for the core holding (use the -21.2% / -40.3% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
-81%30 วันก่อน PDUFA

Inverted versus the normal pattern — instead of drifting up into the event, CAPR lost 81% in the 30 days before it as the FDA briefing document and AdCom vote landed. The pre-catalyst move already happened, in the wrong direction.

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +115%
range: +80% to +210%· Jun 2023
An approval over a 9-3 negative AdCom would be a genuine surprise and would re-rate the stock violently off a washed-out base. SRPT (Jun 2023) is the precedent for approval despite advisory controversy, though its vote was far closer than 9-3.
❌ Catalyst Missavg -45%
range: -30% to -60%· Jul 2025
Shallower than the usual -40% to -80% CRL range only because the stock already fell 81% ahead of the decision — much of the CRL is priced. CAPR's own first-cycle CRL (Jul 2025) took it down 30%.
💼Spot Position Sizing
How the recommended % is derived
1%
of portfolio

Cut from 3% in the prior report. A 9-3 negative efficacy vote plus active securities litigation is not a 3% conviction position — 1% is ค่าขนม sizing on a low-probability regulatory reversal.

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-21.2%($3.3)
A break here before Aug 22 means the market has fully given up on approval
After Catalyst (Bad Result)-40%
On a CRL, exit into the first liquidity — the next step is a new trial, measured in years
📎 Sources

Generated 2026-08-13 · Not financial advice